Skip to content

Study · In vitro (cell-free) · rhesus monkey and rat · 1985

3 results

Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist.

Chan RL, Chaplin MD

Biochemical and biophysical research communications1 Mar 1985Cited by 15 (Europe PMC)

PMID3156598 (opens in a new tab)DOI10.1016/s0006-291x(85)80214-x (opens in a new tab)PepBankPUB-03156598
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Pharmacokinetics

    In laboratory plasma tests, 78-84% of nafarelin was protein-bound versus 22-25% of LHRH across tested concentrations.

    In plain wordsIn lab tests, nafarelin bound more strongly to undiluted plasma proteins than LHRH.

    Peptide
    Nafarelin
    Outcome
    IncreaseBinding to undiluted plasma
    Study

    human, rhesus monkey and ratn: not reported in source

    fresh plasma in equilibrium dialysis
    Comparator
    LHRH
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10(-8) to 10(-5) MAs given in this study (human, rhesus monkey and rat).

    Source sentences

    Summary
    Over a wide range of concentrations (10(-8) to 10(-5) M), 78-84% of nafarelin acetate and only 22-25% of LHRH were bound to undiluted plasma.
    1 context sentence
    Summary · context
    to plasma proteins was investigated in vitro by equilibrium dialysis at 4 degrees C with fresh plasma from normal human subjects, female rhesus monkeys, and female rats.
  2. 02LabIn vitro (cell-free)Pharmacokinetics

    In laboratory tests with 10% plasma, nafarelin binding was 31-37% versus 0.9-4.2% for LHRH.

    In plain wordsIn lab tests with diluted plasma, nafarelin binding was greater than LHRH binding.

    Peptide
    Nafarelin
    Outcome
    IncreaseBinding in diluted plasma
    Study

    human, rhesus monkey and ratn: not reported in source

    fresh plasma in equilibrium dialysis
    Comparator
    LHRH
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    With 10% plasma, the extent of binding was 31-37%, and 0.9-4.2% for nafarelin acetate and LHRH, respectively.
    1 context sentence
    Summary · context
    to plasma proteins was investigated in vitro by equilibrium dialysis at 4 degrees C with fresh plasma from normal human subjects, female rhesus monkeys, and female rats.
  3. 03LabIn vitro (cell-free)Mechanism

    In laboratory plasma tests, albumin played a predominant role in nafarelin binding.

    In plain wordsIn lab tests, albumin played a predominant role in nafarelin binding to plasma proteins.

    Peptide
    Nafarelin
    Outcome
    Not applicableAlbumin contribution to plasma binding
    Study

    human, rhesus monkey and ratn: not reported in source

    fresh plasma in equilibrium dialysis
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Albumin was shown to play a predominant role in the plasma binding of the two compounds.
    1 context sentence
    Summary · context
    to plasma proteins was investigated in vitro by equilibrium dialysis at 4 degrees C with fresh plasma from normal human subjects, female rhesus monkeys, and female rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.